May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
A neuroprotective effect of edaravone, a novel free radical scavenger, on acute phase of retinal ganglion cell degeneration following retinal ischemia/ reperfusion injury in rat.
Author Affiliations & Notes
  • S.–I. Kawai
    Ophthalmology, Saitama Medical Center, Saitama Medical School, Saitama, Japan
    Biochemistry, Saitama Medical School, Saitama, Japan
  • M. Sakurai
    Ophthalmology, Saitama Medical Center, Saitama Medical School, Saitama, Japan
  • T. Komoda
    Biochemistry, Saitama Medical School, Saitama, Japan
  • K. Kawai
    Ophthalmology, Saitama Medical Center, Saitama Medical School, Saitama, Japan
  • Footnotes
    Commercial Relationships  S. Kawai, None; M. Sakurai, None; T. Komoda, None; K. Kawai, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 884. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S.–I. Kawai, M. Sakurai, T. Komoda, K. Kawai; A neuroprotective effect of edaravone, a novel free radical scavenger, on acute phase of retinal ganglion cell degeneration following retinal ischemia/ reperfusion injury in rat. . Invest. Ophthalmol. Vis. Sci. 2004;45(13):884.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: The effects of edaravone (3–methyl–1–phenyl–2–pyrazolin–5–one), a novel free radical scavenger have been found in brain ischemia, model of cochlear ischemia, acute liver injury and pancreatitis. In this study, we evaluated the efficacy of edaravone on retinal ganglion cell (RGC) degeneration may occur due to neurotoxicity of reactive oxygen species (ROS) in rat retinal ischemia/reperfusion injury. Methods: Retinal ischemia in Wistar rats was produced by transient elevation of intraocular pressure by intraocular cannulation (>110mmHg 75min). The effect of edaravone was investigated on four injection routes, intravenous (3mg/kg x3), intraperitoneal (3mg/kg x3), intravitreous (1mg/kg x9), and eye drop (1mg/kg x9) within 24h after ischemia. The dose response (0.3, 1, 3, 6, 10, 30 mg/kg x3) and timing of injection (0, 12, 24, 48, 72, 144h after ischemia) of edaravone was also examined. Aminoguanidine (AG), an inhibitor of inducible nitric oxide synthase, was injected intraperitonealy after ischemia (3mg/kg/day) in two groups. One for injecting only acute phase (0, 1, 2 days after ischemia) and the other one for entire phase. After 1–week reperfusion, loss of RGCs was determined quantitatively by retrograde labeling with Fluoro–Gold. Results: Following ischemia/reperfusion injury, treatment with edaravone significantly reduced the loss of RGCs dose dependently up to 6mg/kg x3. Edaravone injection did not affect afterward 48h reperfusion. The neuroprotective effects were found in groups of intravitreous injection (12% cell loss in central retina, p<0.01), intravenous injection (19% cell loss, p<0.05), and intraperitoneal injection (21% cell loss, p<0.05), compared with control groups (28% cell loss). However, there is no effect with eye drop group (25% cell loss). In compare with edaravone to AG injected only acute phase, edaravone protect RGCs more than AG. Edaravone+AG group had most intensive effect (8% cell loss) compared with edaravone only group (19% cell loss) and AG only in entire phase group (13% cell loss). Conclusions: Edaravone has neuroprotective effect within 48h reperfusion, stronger than AG. ROS play more important role in acute phase of RGCs degeneration following retinal ischemia/reperfusion injury in rat.

Keywords: neuroprotection • antioxidants • nitric oxide 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×